Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

UB 211

Drug Profile

UB 211

Alternative Names: Anti-IgE allergy vaccine - United Biomedical; UB-211

Latest Information Update: 03 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator United Biomedical
  • Class Allergy immunotherapies; Antiallergics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Allergic rhinitis; Hypersensitivity
  • No development reported Asthma

Most Recent Events

  • 03 Jan 2020 Preclinical trials in Hypersensitivity in Taiwan (unspecified route) before January 2020 (United Biomedical pipeline, January 2020)
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Hypersensitivity in USA
  • 25 Sep 2019 Preclinical trials in Allergic rhinitis in USA, before September 2019 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top